Cancer is the leading cause of disease-related deaths among children in high-income countries. Tumor
heterogeneity and lack of mechanism-of-action-based therapeutic options are key challenges to overcome in order
to improve pediatric cancer patients’ survival. Here, we report the EU-IMI-2 funded public-private partnership
“ITCC-Pediatric Preclinical Proof-of-Concept Platform” (ITCC-P4), which has built a large repertoire of
patient-derived xenograft (PDX) models, representing all major solid pediatric cancer types, for in vivo drug
testing. Three-hundred-fifty-three PDX models from diagnostic and relapsed pediatric cancers have been established
and molecularly characterized, together with matched germline/tumor samples. As proof-of-concept, we present in
vivo drug screening data in neuroblastoma and rhabdomyosarcoma models. PDX data, accessible here, allow the
selection of models based on oncogenic drivers and/or potential biomarkers for preclinical testing. Operated by
a non-profit entity (www.itccp4.com), this sustainable platform aids academic and industrial researchers in
developing and prioritizing innovative therapies for pediatric cancer.
Please note that this version has data limited to Driver genes only.
You can apply for
or
.